Sponsor: Regeneron Pharmaceuticals · sponsor also appears in the payment records
Disclosed research payments
$2,249,252
Named PIs
5
- BILAL SIDDIQUI: $843,045
- EDWARD GELMANN: $282,711
- BENEDITO CARNEIRO FILHO: $234,450
Prostate Cancer (advanced/mCRPC): drug payment transparency
Advanced prostate cancer therapy involves choosing among four next-generation androgen-receptor pathway inhibitors with overlapping indications across mHSPC, nmCRPC, and mCRPC settings. The sequencing of these agents with PARP inhibitors (for BRCA/HRR-mutant patients) and radioligand therapy is an area of active clinical debate and substantial promotional spend.
Data from CMS Open Payments (2023–2024) · last checked
The drugs in question
These are the close-substitute branded therapies your oncologist may choose among for prostate cancer (advanced/mcrpc). Generic and biosimilar options may also be available depending on line of therapy.
Androgen receptor pathway inhibitors
- Xtandi (enzalutamide) — Astellas / Pfizer
- Zytiga / Yonsa / generic (abiraterone acetate) — Johnson & Johnson / multiple
- Erleada (apalutamide) — Johnson & Johnson
- Nubeqa (darolutamide) — Bayer / Orion
PARP inhibitors (for BRCA / HRR-mutant disease)
- Lynparza (olaparib) — AstraZeneca / Merck
- Rubraca (rucaparib) — Pharma& / Clovis
- Zejula (niraparib) — GSK
- Talzenna (talazoparib) — Pfizer
Radioligand therapies
- Pluvicto (lutetium-177 vipivotide tetraxetan) — Novartis
- Xofigo (radium-223 dichloride) — Bayer
Top paying manufacturers to oncologists in our index
Across all oncologists in our index (all cancer types), these are the companies making these prostate cancer (advanced/mcrpc) drugs, summed across their latest reported year of disclosures. Payments include both general and research categories; see methodology for the split.
| Manufacturer | Total disclosed to oncologists (latest year) |
|---|---|
| AstraZeneca | $11,913,894 |
| Pfizer | $8,033,132 |
| Merck | $5,435,449 |
| Novartis | $2,644,139 |
| Astellas | $1,725,342 |
| Bayer | $950,975 |
| Orion | $4,115 |
| Johnson & Johnson | $1,618 |
prostate cancer (advanced/mcrpc) trials with research-payment cross-reference
Active prostate cancer (advanced/mcrpc) trials in our database where one or more research-payment records (tied to the trial's NCT ID) are disclosed in CMS Open Payments. We show the disclosed principal investigators and amounts. The presence of research payments on a trial is expected — industry-funded clinical trials pay the physicians running them for site work — but knowing the scale gives you useful context.
Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T
NCT06134232Sponsor: Dendreon · sponsor also appears in the payment records
Disclosed research payments
$684,938
Named PIs
5
- CHRISTOPHER PIECZONKA: $53,908
- LAURENCE BELKOFF: $45,173
- RONALD TUTRONE: $44,950
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
NCT06465069Sponsor: Eli Lilly and Company · sponsor also appears in the payment records
Disclosed research payments
$427,568
Named PIs
5
- ALEXANDER WEI: $85,059
- XIN GAO: $80,359
- MATTHEW GALSKY: $79,328
Sponsor: Northwestern University
Disclosed research payments
$151,334
Named PIs
1
- ASHLEY ROSS: $151,334
Sponsor: Brigham and Women's Hospital
Disclosed research payments
$135,274
Named PIs
1
- HEATHER JACENE: $135,274
Sponsor: AdventHealth
Disclosed research payments
$34,428
Named PIs
1
- GURU SONPAVDE: $34,428
Questions to ask your oncologist
- Among the approved options for my stage and biomarker profile, which do you recommend, and why this one over its close substitutes?
- Have you received consulting, speaking, or research payments from the maker of the drug you're recommending? (Every U.S. physician can look themselves up at openpaymentsdata.cms.gov.)
- Are there cooperative-group or NIH-sponsored trials I should consider, in addition to industry-sponsored ones?
- What do the published head-to-head trials show for the option you're recommending versus its substitutes?
A financial relationship between a physician and a manufacturer is not, on its own, a problem — it is the expected context of modern drug development. The purpose of federal disclosure is to let you ask informed questions, not to make the decision for you.
More on prostate cancer (advanced/mcrpc)
Medical disclaimer: This page aggregates public federal data and is not medical advice. Drug choice for any individual patient depends on stage, biomarker profile, prior therapy, comorbidities, and patient preference — decisions that must be made with your licensed care team.
About the payment data: Figures are disclosed by manufacturers to CMS under the Physician Payments Sunshine Act (42 U.S.C. §1320a-7h). Presence of payments is not a conflict of interest. Physicians who believe a record is wrong file a correction through the CMS dispute process.
Sources: CMS Open Payments · ClinicalTrials.gov · Data fetched: 2026-04-21 · full methodology